Dr. Guido A. Davidzon is a physician-scientist board certified in Nuclear Medicine. He graduated with honors from medical school in Argentina and completed an internship at Yale University New-Haven Hospital in Connecticut. He did his residency and was chief resident at Stanford Health Care. He completed a research fellowship in mitochondrial diseases at Columbia University in New York and, a U.S. National Library of Medicine Award supported, Biomedical Informatics fellowship at Massachusetts General Hospital in conjunction with a Science Masters at MIT.
Dr. Davidzon is Clinical Assistant Professor in the Department of Radiology at Stanford University and Chobanian and Avedisian School of Medicine. His clinical specialties include early diagnostic imaging of cancer, coronary artery disease, and dementias using molecular probes as well as the treatment of cancer for which he employs targeted radiopharmaceutical therapy.
Dr. Davidzon investigates the use of machine learning in medical imaging to improve clinical outcomes, he is involved in the professional Society of Nuclear Medicine and Molecular Imaging. He serves as a peer reviewer for multiple medical journals. Dr. Davidzon is a native of Buenos Aires, Argentina and has lived in the U.S. for over a decade. He travels to Argentina frequently, with his wife and three sons.
Kaiser Permanente Santa Clara Medical Center
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 61 results.
Duan H, Ferri V, Fisher GA, Shaheen S, Davidzon GA, Iagaru A, Mari Aparici C. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. Oncologist. 2022 Jun 08; 27(6):447-452. PMID: 35641196; PMCID: PMC9177120; DOI: 10.1093/oncolo/oyab072;
Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 May 12. PMID: 35552245
Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, Loening AM, Ghanouni P, Sonn G, Iagaru A. 68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. J Nucl Med. 2022 May 05. PMID: 35512996
Napolioni V, Fredericks CA, Kim Y, Channappa D, Khan RR, Kim LH, Zafar F, Couthouis J, Davidzon GA, Mormino EC, Gitler AD, Montine TJ, Schüle B, Greicius MD. Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders. Biomedicines. 2022 Jan 12; 10(1). PMID: 35052839; PMCID: PMC8774039; DOI: 10.3390/biomedicines10010160;
Hall JN, Mormino E, Ng A, Boumis A, Gaudioso JL, Davidzon GA, Sha SJ. Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab. JAMA Neurol. 2022 01 01; 79(1):87-89. PMID: 34747986; PMCID: PMC9677548; DOI: 10.1001/jamaneurol.2021.3933;
Duan H, Baratto L, Hatami N, Liang T, Mari Aparici C, Davidzon GA, Iagaru A. 68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Transl Oncol. 2022 Jan; 15(1):101293. PMID: 34823095; PMCID: PMC8626686; DOI: 10.1016/j.tranon.2021.101293;
Chaudhari AS, Mittra E, Davidzon GA, Gulaka P, Gandhi H, Brown A, Zhang T, Srinivas S, Gong E, Zaharchuk G, Jadvar H. Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study. NPJ Digit Med. 2021 Sep 14; 4(1):139. PMID: 34521985; PMCID: PMC8440668; DOI: 10.1038/s41746-021-00512-6;
Beinat C, Patel CB, Haywood T, Murty S, Naya L, Castillo JB, Reyes ST, Phillips M, Buccino P, Shen B, Park JH, Koran MEI, Alam IS, James ML, Holley D, Halbert K, Gandhi H, He JQ, Granucci M, Johnson E, Liu DD, Uchida N, Sinha R, Chu P, Born DE, Warnock GI, Weissman I, Hayden-Gephart M, Khalighi M, Massoud TF, Iagaru A, Davidzon G, Thomas R, Nagpal S, Recht LD, Gambhir SS. A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6467-6478. PMID: 34475101; PMCID: PMC8639752; DOI: 10.1158/1078-0432.CCR-21-0544;
Chaudhari AS, Mittra E, Davidzon GA, Gulaka P, Gandhi H, Brown A, Zhang T, Srinivas S, Gong E, Zaharchuk G, Jadvar H. Low-count whole-body PET with deep learning in a multicenter and externally validated study. NPJ Digit Med. 2021 Aug 23; 4(1):127. PMID: 34426629; PMCID: PMC8382711; DOI: 10.1038/s41746-021-00497-2;
Baratto L, Toriihara A, Hatami N, Aparici CM, Davidzon G, Levin CS, Iagaru A. Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. Diagnostics (Basel). 2021 May 30; 11(6). PMID: 34070751; PMCID: PMC8228776; DOI: 10.3390/diagnostics11060992;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.